Severe acute respiratory syndrome coronavirus 2

Worldwide Vaccine Contract Manufacturing Industry to 2027 - Increase in Initiatives Favouring Vaccinations is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, COVID-19, Human services, Safety, Membrane protein, Research, Awareness, Vaccine, Disease, Hepatitis, Scientific Reports, Health, Sissel v. United States Department of Health & Human Services, Hepatitis B, Infection, Capsid, Severe acute respiratory syndrome coronavirus 2, Multi, Population, SARS, Growth, Envelope, Adoption

These advantages are expected to propel the growth of the inactivated vaccine segment in the vaccine contract manufacturing market in the forecast period.

Key Points: 
  • These advantages are expected to propel the growth of the inactivated vaccine segment in the vaccine contract manufacturing market in the forecast period.
  • These advantages of inactivated vaccines and the growing research on the vaccine production during the COVID-19 is adding to the growth of the vaccine contract manufacturing market.
  • The rising number of COVID-19 cases in the North American region is adding to the growth of the vaccine contract manufacturing market.
  • The large population affected by the SARS-CoV2 infection and the increase in the necessity of vaccine contract manufacturing for the ease of treatment of such infections is expected to propel the growth of the vaccine contract manufacturing market.

ATMOFIZER TECHNOLOGIES INC. Announces LATEST Independent test results

Retrieved on: 
Thursday, August 25, 2022
Phrase, COVID-19, Technology, View, Virus, Risk, Food, Surrogate, Food and Drug Administration, HEPA, Atmosphere, Patent, Multimedia, Severe acute respiratory syndrome coronavirus 2, Company, FDA, SEDAR, Intellectual property, Industry, Health, Bacteria, Efficiency, Nature, Risk management

The Food and Drug Administration (FDA) has not evaluated Atmofizer technology.

Key Points: 
  • The Food and Drug Administration (FDA) has not evaluated Atmofizer technology.
  • Atmofizer ONE has not been reviewed or approved by the FDA.
  • Atmofizer's consumer and industrial solutions are based on its patent-protected and patent pending technology for ultrafine particle agglomeration and neutralization.
  • Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while lowering customers' operational costs.

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

Retrieved on: 
Thursday, August 25, 2022
European Medicines Agency, LINK, COVID-19, EMA, Safety, Vaccination, Ageing, Development, WHO, Vaccine, National Medical Products Administration, Coalition, Aluminium, CEPI, Licensure, Adolescence, NMPA, Severe acute respiratory syndrome coronavirus 2, GLOBE, CpG, Population, Adult, World, Epidemic, SCB-2019, 1018, Profile, Forward-looking statement, Coalition for Epidemic Preparedness Innovations, World Health Organization, Pharmaceutical industry, Clover, Trimer

SHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced positive data from a global Phase 2/3 trial evaluating Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), in adolescents (aged 12 to 17 years). The study successfully met the primary endpoint and demonstrated that vaccination with SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents compared to young adults (aged 18 to 25 years), a population where SCB-2019 (CpG 1018/Alum) had previously been demonstrated to be highly protective against COVID-19. Clover plans to submit the data and seek licensure in adolescents from global regulatory authorities, in addition to its ongoing submissions to the China National Medical Products Administration (NMPA), the European Medicines Agency (EMA), and the World Health Organization (WHO) for use in adults and elderly, to broaden the potential use of SCB-2019 (CpG 1018/Alum) across age groups and as a universal COVID-19 booster vaccine.

Key Points: 
  • We are highly encouraged by these positive pivotal Phase 2/3 trial data in adolescents.
  • The Phase 2/3 trial in adolescents enrolled 1,278 participants and evaluated the immunogenicity, safety, and efficacy of SCB-2019 (CpG 1018/Alum) vaccine, administered as 2 doses given 21 days apart.
  • These study results will contribute to the SCB-2019 (CpG 1018/Alum) data package and the licensure pathway for Clovers COVID-19 vaccine candidate in adolescents.
  • Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavaxs (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain

Retrieved on: 
Wednesday, August 24, 2022
Research, Surgery, Infectious Diseases, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Chronic pain, COVID-19, Osteoarthritis, University, Security (finance), Post-traumatic stress disorder, Cancer, Securities Exchange Act of 1934, Securities Act of 1933, CNS, OTC, Central nervous system, Efficiency, NASDAQ, Perioperative medicine, PTSD, World Institute of Pain, Poster, Department, Pain management, U.S. Securities and Exchange Commission, Faculty, Severe acute respiratory syndrome coronavirus 2, MD, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., FDA, Company, MET, Congress, Epilepsy, Private Securities Litigation Reform Act, Bupivacaine, WIP, Industry, Nature, Pharmaceutical industry, Dentistry, Risk management, CBD, Medicine, Anesthesiology, Pain, Safety

The World Congress of Pain will take place in Budapest, Hungary, from August 25th through the 27th.

Key Points: 
  • The World Congress of Pain will take place in Budapest, Hungary, from August 25th through the 27th.
  • The World Institute of Pain was founded in 1993 as a worldwide organization that aims to promote the best practice of pain medicine for the 21st century.
  • Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery.
  • Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms.

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, August 24, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, NRC, National, GLP, COVID-19, Human, CEO, Immunoglobulin A, Immunization, NYSE, Research, Hand, Vaccine, Toxicity, National Research Council, Mouse, Infection, Scientific Reports, Blood, Good laboratory practice, NIH, Patent, U.S. Securities and Exchange Commission, Rabbit, Severe acute respiratory syndrome coronavirus 2, Antibody, Company, FDA, Communication, Toxicology, Immunoglobulin G, Private Securities Litigation Reform Act, Bacteria, Trial of the century, Viral load, Nature, Oragene

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced favorable preliminary results from its ongoing Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced favorable preliminary results from its ongoing Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.
  • We believe our intranasal vaccine candidate will have the potential to reduce transmission and offers a needle-free COVID-19 vaccine option.
  • Our intranasal vaccine candidate has previously shown strong immune responses in preclinical studies against multiple SARS-CoV-2 variants of interest.
  • Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.

SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19

Retrieved on: 
Wednesday, August 24, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, ABC International, COVID-19, Research, CEO, RNA, Traction, OurCrowd, Doctor of Philosophy, Central Drugs Standard Control Organisation, Nitric oxide, Disease, Gel, Sale, Infection, Pulmonary hypertension, LinkedIn, Union, Blue baby syndrome, Severe acute respiratory syndrome coronavirus 2, PCR, CDSCO, Bath, Omicron, Horizons Ventures, Observational study, NO, Twitter, Adult, Risk, Hispanic Council On Social Policy Center For Community Development Corp., CE, Health, NORS, Trial of the century, Viral load, Patient, Bronchoalveolar lavage, Pharmaceutical industry, BC

SaNOtize Research & Development Corp., (SaNOtize), a Canadian anti-infective-focused therapeutics company, today announced an oversubscribed $24 million Series B funding to advance its nitric oxide-based therapeutics pipeline.

Key Points: 
  • SaNOtize Research & Development Corp., (SaNOtize), a Canadian anti-infective-focused therapeutics company, today announced an oversubscribed $24 million Series B funding to advance its nitric oxide-based therapeutics pipeline.
  • Our clinical and observational studies found NONS to be safe and effective at both treating and preventing COVID-19, even amid delta and omicron surges.
  • We look forward to expanding our clinical research and working toward regulatory approval in the United States and Canada.
  • SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide.

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

Retrieved on: 
Tuesday, August 23, 2022
AstraZeneca, COVID-19, EMA, Public health, EU, Technology, Vaccination, WHO, Vaccine, VLA, Strategic Advisory Group of Experts, Infection, Lyme disease, Euronext Paris, Severe acute respiratory syndrome coronavirus 2, MD, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, World, VLA2001, 1018, SAGE, Review, World Health Organization, Pharmaceutical industry, Kingdom, Immunization, Valneva SE

Saint-Herblain (France), August 23, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Companys inactivated COVID-19 vaccine.

Key Points: 
  • Saint-Herblain (France), August 23, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Companys inactivated COVID-19 vaccine.
  • WHO may further update its interim recommendations to include additional uses of Valnevas COVID-19 vaccine as new data are made available.
  • Valneva currently has agreements to supply VLA2001 to certain EU Member States2 and the Kingdom of Bahrain3.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

MAKO Medical Ranked as Top Growing Company by Inc. 5000

Retrieved on: 
Tuesday, August 23, 2022
COVID-19, Monkeypox, Veteran, Technology, American, Applied Biosystems, Forbes, MAKO, American City Business Journals, United, RT, Privately held company, Physician, CAP, Hospital, Severe acute respiratory syndrome coronavirus 2, COVID-19 testing, Inc. (magazine), Growth, Veterans Day, CDC, Pharmaceutical industry, Medical device

For the second time, MAKO has been ranked among Inc. 5000's fastest growing privately held companies in the nation.

Key Points: 
  • For the second time, MAKO has been ranked among Inc. 5000's fastest growing privately held companies in the nation.
  • August 2022, Inc. Magazine recognized MAKO Medical as one of America's Fastest Growing Private Companies.
  • August 2020, MAKO Medical announced the company scored 100% on CAP COVID Proficiency Testing, demonstrating MAKO's commitment to quality lab results.
  • Founded in 2014, MAKO Medical is a diagnostics partner for businesses, physicians, urgent care facilities, and hospitals around the United States.

Europe Disposable Endoscopes Market Report 2022: Growing Number of Chronic and Respiratory Diseases in Europe and the Shortage of Medical Staff for Disinfecting Reusable Endoscopes Driving Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Health, Medical Supplies, Medical Devices, COVID-19, Conditional sentence, ENT, Safety, Nose, Chapter Seven, Endoscopy, USD, National Association Medical Staff Services, Infection, Foreign Bodies, Bronchoscopic lung volume reduction (BLVR), European Respiratory Society, Hospital, Chapter Three, Cross Contamination, Clogging, Severe acute respiratory syndrome coronavirus 2, Chest (journal), CAGR, COPD, Degenerative disease, Leakage, Risk, Country, Bronchoscopy, Ear, Growth, Adoption, Efficiency, Medical device, Vaccine, Application, Arthroscopy

The Europe disposable endoscopes market size is expected to reach USD 1.8 billion by 2030.

Key Points: 
  • The Europe disposable endoscopes market size is expected to reach USD 1.8 billion by 2030.
  • The increasing cases of cross-contamination complications due to the use of reusable endoscopes are driving the adoption of single-use endoscopic devices.
  • In addition, the growing number of chronic and respiratory diseases in Europe and the shortage of medical staff for cleaning and disinfecting reusable endoscopes in between the surgical procedures drive the market for disposable endoscopes.
  • Europe Disposable Endoscopes Market: Country Estimates & Trend Analysis, by Application, by End Use

Voran Group Obtains Health Canada Authorization on Disinfectant With 30-Second COVID Kill Claim

Retrieved on: 
Monday, August 22, 2022
Health, Chemicals, Plastics, Infectious Diseases, Manufacturing, Other Health, COVID-19, Biotechnology, COVID-19, CEO, Aviation, Disinfectant, Staphylococcus aureus, Salmonella enterica, Sale, Infection, Salmonella, Health Canada, Multimedia, Hospital, Pseudomonas aeruginosa, Severe acute respiratory syndrome coronavirus 2, Movement, AMS, Health, Monkeypox, Boeing, Pharmaceutical industry, Airline

Today, Voran Group Ventures Ltd (Voran Group) announces the receipt of market authorization from Health Canada on new efficacy claims for its made-in-Canada disinfectant solution, Bacoban (106) Cleaner & Disinfectant.

Key Points: 
  • Today, Voran Group Ventures Ltd (Voran Group) announces the receipt of market authorization from Health Canada on new efficacy claims for its made-in-Canada disinfectant solution, Bacoban (106) Cleaner & Disinfectant.
  • Bacoban (106) Cleaner & Disinfectant, a multi-functional surface cleaner and disinfectant, has been tested by an accredited, independent lab using internationally recognized standardized methods following Health Canada's testing guidelines.
  • As per Health Canadas Interim Guidance on monkeypox within healthcare settings4, it is recommended to clean and disinfect with a Health Canada approved disinfectant following the manufacturers recommendations."
  • About Voran Group: Based in Sherwood Park, Alberta, Voran Group delivers comprehensive made-in-Canada antimicrobial solutions to industrial, commercial, and healthcare industries.